ThermoGenesis to develop COVID-19 therapeutics

By The Science Advisory Board staff writers

April 13, 2020 -- ThermoGenesis has announced that its joint venture, ImmuneCyte Life Sciences, has acquired intellectual property for developing antibody therapeutics for COVID-19.

The intellectual property ImmuneCyte has purchased includes four monoclonal antibody drug candidates against SARS-CoV-2, which were obtained from B cell samples from patients who recovered from the disease. The drug candidates were initially developed by researchers at East China Normal University in Shanghai.

ThermoGenesis is also developing a treatment called convalescent plasma therapy that gives patients a plasma infusion from people who have recovered from COVID-19 using its SARS-CoV-2 (COVID-19) IgM/IgG Antibody Fast Detection kit, it said.

SARS-CoV-2 vaccine utilizing microneedle arrays appears in the literature
Within four weeks of the SARS-CoV-2 spike sequence becoming available, researchers from the University of Pittsburgh School of Medicine developed immunogens...
Applied DNA, Takis expand COVID-19 vaccine development
Applied DNA and Takis Biotech have added a fifth candidate to their COVID-19 vaccine development program, increasing the chances of a successor emerging.
Kleo, Green Cross collaborate on COVID-19 NK combination therapy
Kleo Pharmaceuticals is joining forces with Green Cross LabCell of South Korea to advance testing of natural killer (NK) cell therapies as a potential...
Generation Bio, Vir partner for mAbs against COVID-9
Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes...
Xencor, Vir partner on COVID-19 antibodies research
Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments...

Copyright © 2020 scienceboard.net


Conferences
Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter